Rate Video

VJVirtual | Updates in ALK+ NSCLC

Ross Camidge • 26 Mar 2020

Lung Cancer Non-Small Cell Lung Cancer

Ross Camidge, MD, PhD, University of Colorado Aurora, Colorado, USA, discusses updates in anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC) and his thoughts on interpreting the data from clinical trials to better treat patients. This interview was recorded via an online conference call with The Video Journal of Oncology (VJOncology).

COVID-19 & treating patients with lung cancer

Ross Camidge • 26 Mar 2020

Sym015: MET antibody mixture for advanced solid tumors

Ross Camidge • 28 Sep 2019

Breakthroughs in lung cancer from ASCO 2018: positive and negative

Ross Camidge • 1 Jun 2018

Using emibetuzumab directed towards MET for the treatment of lung cancer

Ross Camidge • 3 Jun 2016

Related Videos

Building a clinical research platform to capture and leverage data from cancer care in Germany

Frank Griesinger

ctDNA measurement via liquid biopsy: improving cancer detection and diagnosis

Pierre-Jean Lamy

How to discuss immunotherapy as a treatment option with lung cancer patients

Clinical factors in the selection of patients for first-line immunotherapy of lung cancer